

HEPATITIS C TREATMENT UPDATE

In the last two years, four new Hepatitis C treatments have been introduced that have significantly changed treatment expectations and costs for a course of treatment. The Division of Medicaid (DOM) has developed new prior authorization criteria several times as these new products have entered the market. The current DOM PDL is shown below.

Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) was recently introduced to the market but has not yet been reviewed by the DOM P&T Committee. Due to the high cost of the new treatment options, utilization is being closely monitored.

Hepatitis C Treatments by Pharmacy Plan and Month																
Month	Fee-For-Service					Magnolia					United Health Care					
	Product					Product					Product					
	HAR	OLY	SOV	VIC	Total	HAR	OLY	SOV	VIC	Total	HAR	OLY	SOV	VIC	Total	
2014	Jan	0	0	1	0	1	0	0	0	2	2	0	0	3	0	3
	Feb	0	1	2	0	3	0	0	4	4	8	0	0	6	0	6
	Mar	0	0	1	0	1	0	0	3	2	5	0	1	9	0	10
	Apr	0	3	5	0	8	0	0	6	2	8	0	1	13	0	14
	May	0	4	7	0	11	0	0	7	0	7	0	1	8	0	9
	Jun	0	3	8	0	11	0	0	25	1	26	0	3	9	0	12
	Jul	0	1	4	0	5	0	0	16	0	16	0	2	7	0	9
	Aug	0	0	5	0	5	0	0	14	0	14	0	3	9	0	12
	Sep	0	1	7	0	8	0	0	14	0	14	0	1	5	0	6
	Oct	0	4	11	0	15	1	0	15	0	16	0	1	4	0	5
	Nov	0	1	8	0	9	2	1	7	0	10	0	0	2	0	2
	Dec	3	1	7	0	11	6	0	9	0	15	0	3	5	0	8
2015	Jan	1	0	2	0	3	0	0	0	0	0	0	0	0	0	0
Total		4	19	68	0	91	9	1	120	11	141	0	16	80	0	96

HAR = Harvoni; OLY = Olysio; SOV = Sovaldi; VIC = Victrelis

NO ACTION NEEDED: This is a report to the DUR Board on utilization trends in the three pharmacy plans for information and discussion purposes only. No action is being sought at this time.